血小板衍生生长因子在尿毒症血管钙化中的作用
该研究探讨PDGF/PDGFR-β在CKD血管钙化中的作用。采用小鼠主动脉离体钙化模型、VSMC特异性诱导表达组成性激活PDGFR-β的转基因小鼠及CKD患者动脉标本。发现尿毒症条件下PDGFR-β磷酸化增加并促进血管钙化,抑制PDGF信号可减少钙化并增强血管弹性,PDGFR-β是潜在治疗靶点。
要点
- 尿毒症透析液或CKD动物主动脉中PDGFR-β磷酸化及血管钙化增加。
- 抑制PDGF信号可减少尿毒症钙化并增强血管弹性。
- CKD5期患者动脉中磷酸化PDGFR-β升高并伴VSMC表型转换。
核心结论
- PDGFR-β参与CKD相关血管钙化,是潜在的新治疗靶点。
研究设计与样本
- 采用小鼠主动脉离体钙化模型模拟尿毒症条件。
- 构建VSMC特异性诱导表达组成性激活PDGFR-β的转基因小鼠并建立加速血管钙化与CKD的体内模型。
- 比较CKD5期患者与年龄性别匹配无CKD且无钙化动脉患者的动脉标本。
主要发现
- 与对照相比,尿毒症患者透析液孵育小鼠主动脉或CKD动物主动脉均显示PDGFR-β磷酸化增加和血管钙化增加。
- 使用可溶性PDGFR-β或小分子酪氨酸激酶抑制剂伊马替尼抑制PDGF信号,可减少尿毒症钙化并增强血管弹性。
- 转基因小鼠主动脉离体钙化增加,尿毒症条件进一步加重,提示VSMC表型转换。
- CKD5期患者动脉中磷酸化PDGFR-β表达增加并伴VSMC表型转换。
临床怎么用
- PDGFR-β信号通路可作为CKD相关血管钙化的潜在干预靶点。
- 伊马替尼等PDGF信号抑制剂在实验中减少尿毒症钙化,但尚未转化为临床推荐。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vascular calcification is common in chronic kidney disease (CKD), contributing to increased cardiovascular morbidity and mortality. A proposed mechanism for driving vascular calcification is a phenotypic switch of vascular smooth muscle cells (VSMCs). The platelet derived growth factors (PDGFs) and their receptors (PDGFRs), particularly PDGFR-β, were shown to modulate the VSMC phenotype. However, their role in uremic vascular calcification remained unclear. METHODS: To study this, we adapted an ex vivo calcification model using murine aortas to simulate uremic conditions. Next, we generated transgenic mice with a VSMC-specific, inducible expression of constitutively active PDGFR-β and established an in vivo model of accelerated vascular calcification and CKD in the transgenic mice. RESULTS: Compared to control conditions, incubation of mouse aortas with dialysis fluid from uremic patients on hemodialysis therapy or examination of aortas from CKD animals both revealed increased PDGFR-β phosphorylation and vascular calcification. Inhibition of PDGF signaling using soluble PDGFR-β or the small molecule tyrosine kinase inhibitor imatinib reduced uremic calcification and enhanced vascular elasticity. Next, we generated transgenic mice with a VSMC-specific, inducible expression of constitutively active PDGFR-β. The aortas of these mice exhibited increased calcification ex vivo, which was further aggravated by uremic conditions, attesting a phenotypic switch of VSMCs compared to non-transgenic littermates. Finally, increased expression of phosphorylated PDGFR-β and a VSMC phenotypic switch were detected in arteries from patients with CKD stage 5 compared to age- and sex-matched patients without CKD and with non-calcified arteries. CONCLUSIONS: PDGFR-β contributes to CKD-associated vascular calcification, representing a potential novel therapeutic target.
引用
- Öztürk BY, Zhang L, von Stillfried S, et al. The role of platelet-derived growth factor in uremic vascular calcification. Kidney Int. 2026. PMID: 42302932. doi:10.1016/j.kint.2026.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。